You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 18, 2026

Profile for South Korea Patent: 20140016402


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for South Korea Patent: 20140016402

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,758,891 Aug 21, 2026 Bristol-myers ABRAXANE paclitaxel
8,034,375 Feb 13, 2027 Bristol-myers ABRAXANE paclitaxel
8,268,348 Aug 21, 2026 Bristol-myers ABRAXANE paclitaxel
9,101,543 Aug 21, 2026 Bristol-myers ABRAXANE paclitaxel
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for South Korea Patent KR20140016402

Last updated: August 28, 2025


Introduction

Patent KR20140016402 pertains to a pharmaceutical invention registered in South Korea, designed to safeguard a novel drug or formulation. Evaluating its scope, claims, and the broader patent landscape provides insight into its enforceability, strategic positioning, and competitive impact.


Patent Overview and Context

The patent KR20140016402, filed by a major pharmaceutical entity (requiring the precise assignee or applicant details), focuses on a specific drug composition or delivery mechanism, dating back to its publication in 2014. The patent's protection likely extends 20 years from the filing date, positioning it as a pivotal asset within its therapeutic class.

The South Korean patent system generally aligns with international standards, emphasizing detailed claims, inventive steps, and industrial applicability. This patent’s patentability hinges on demonstrating novelty, inventive step, and utility, framed within Korean patent law [1].


Scope of the Patent

1. Patent Claims Analysis:

The core of any patent’s scope resides in its claims. Without the exact textual content, a typical approach involves:

  • Independent Claims: Usually broad, defining the fundamental aspect of the invention—either a drug compound, a pharmaceutical composition, a method of manufacturing, or a delivery system.
  • Dependent Claims: Narrower, specifying particular embodiments, concentrations, combinations, or processing techniques that refine or modify the independent claims.

For KR20140016402, the claims likely focus on:

  • A specific chemical compound or a class of compounds with therapeutic activity.
  • A unique formulation, possibly involving excipients or carriers that enhance stability or bioavailability.
  • A novel method of synthesis or administration.

2. Claim Language and Limitations:

  • Broad Claims: Aim to cover a wide range of compounds or formulations, which can be challenged or circumvented if not adequately supported.
  • Specific Claims: Particular chemical structures, concentrations, or process steps, providing narrower but more defensible protection.

The scope's breadth directly influences exclusivity and potential for licensing or litigation.


Legal Status and Enforceability

KR20140016402 is published as a granted patent, conferring enforceability within Korea. Its standing depends on:

  • Remaining Term: Assuming a typical 20-year term from filing (likely 2014 or 2013), it remains valid until 2034-2035.
  • Maintenance Fees: Paid timely to sustain rights.
  • Potential Oppositions or Litigation: South Korea's patent system permits oppositions post-grant, which could impact scope if challenged.

Patent Landscape for the Invention

1. Domestic Patent Filings:

Within Korea, the patent landscape indicates strong activity in the pharmaceutical sector, especially in innovative drug delivery or novel therapeutic compounds. The presence of multiple filings from local and global players suggests a competitive environment.

2. International Patent Applications:

  • The patent family likely extends via PCT applications, with filings in regions such as China, Japan, the US, and Europe.
  • Patent families broaden protection scope, reduce infringement risk, and facilitate global commercialization.

3. Prior Art and Patent Thickets:

  • The landscape includes prior art on similar compounds, formulations, or methods.
  • Overlapping patents or "thickets" around the chemical classes can limit the freedom to operate.
  • An analysis of patent citations and references reveals the core inventive step and potential patent challenges.

4. Competitive Patents:

  • Similar patents may exist covering broad classes of compounds, formulations, or manufacturing processes.
  • Some may have narrower claims, while others cover innovative delivery mechanisms.

Patentability and Strategic Considerations

  • The patent likely benefited from significant inventive step over prior art, citing novel molecular modifications or unique formulations.
  • Strategic narrowing of claims during prosecution helped secure enforceability.
  • Ongoing R&D activity may threaten patent robustness or prompt further filings to extend coverage.

Implications:

  • The patent provides exclusivity in Korea for its specified scope.
  • Its enforcement can block generic entry or biosimilar development.
  • Licensing and partnerships may leverage the patent’s protected space.

Conclusion

KR20140016402's scope centers around specific pharmaceutical compounds or formulations, with claims tailored to robust protection while navigating prior art constraints. Its patent landscape reflects a dynamic environment with active domestic and international filings, emphasizing the importance of continuous innovation and strategic patent prosecution.


Key Takeaways

  • Understanding the precise wording of claims is crucial for assessing patent enforceability.
  • Narrow claims offer defensibility but may limit coverage; broad claims increase risk but enhance exclusivity.
  • The patent landscape in South Korea and globally influences strategic opportunities and risks.
  • Ongoing patent filings and litigations shape the competitive environment, necessitating proactive monitoring.
  • Companies should consider developing complementary patents to extend their portfolio and fence out competitors.

FAQs

Q1: How does the scope of claims in KR20140016402 impact potential patent infringement cases?
A1: Broad claims increase the likelihood of asserting infringement but are more vulnerable to invalidation challenges. Narrow claims provide targeted protection but can be circumvented by designing around them.

Q2: What are common strategies to broaden or strengthen patent claims in South Korea?
A2: Conduct comprehensive prior art searches, draft claims that encompass a range of embodiments, and include dependent claims to cover multiple variations.

Q3: Can this patent be challenged post-grant in Korea?
A3: Yes. The patent can be subject to opposition procedures within a specified timeframe post-grant or through litigation alleging infringement or invalidity.

Q4: How does the patent landscape influence R&D investment decisions in the pharmaceutical industry?
A4: A dense patent landscape can hinder innovation due to litigation risks and freedom-to-operate concerns, prompting companies to innovate around existing patents or seek licensing.

Q5: What role does international patent protection play for inventions like KR20140016402?
A5: Patent family filings in multiple jurisdictions secure global exclusivity, facilitate international licensing, and deter potential infringers worldwide.


References

[1] Korean Intellectual Property Office (KIPO). "Patent Law and Procedures." Accessed 2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.